

<b>Reference:</b>	FOI.15260.24
<b>Subject:</b>	Intra-vitreous injections or implants
<b>Date of Request:</b>	12 September 2024

**Requested:**

How many of the following intra-vitreous injections/implants has your trust administered in the four-month period from May to August 2024:

- Aflibercept
- Bevacizumab - Avastin
- Bevacizumab - Biosimilar
- Brolucizumab
- Dexamethasone
- Faricimab
- Fluocinolone acetonide
- Ranibizumab - Lucentis (pre-filled syringes)
- Ranibizumab - Lucentis (vials)
- Ranibizumab - Ongavia
- Ranibizumab - Ximluci

**Response:**

Hywel Dda University Health Board (UHB) provides, within the table overleaf, the number of intravitreal injections/implants administered, for the medications listed, during the period 1 May to 31 August 2024.

<b>Medication</b>	<b>Number</b>
Aflibercept	1,265
Bevacizumab - Avastin	0
Bevacizumab - Biosimilar	0
Brolucizumab	0
Dexamethasone	95
Faricimab	710
Fluocinolone acetonide	2
Ranibizumab - Lucentis (pre-filled syringes)	13
Ranibizumab - Lucentis (vials)	0
Ranibizumab - Ongavia	1,638
Ranibizumab - Ximluci	0